Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Journal of Viral Hepatitis

• Publication date

  2004-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1046/j.1365-2893.2003.00487.xPMID 14996343
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

  2003cited by this paper
• Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)

  2003cited by this paper
• Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B

  2003cited by this paper
• Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

  2002cited by this paper
• Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis

  2002cited by this paper
• Evidence for the efficacy of peginterferon alfa-2a (40 KD) (PEGASYS) in the treatment of HBeAg-positive chronic hepatitis B (CHB) and impact of baseline factors

  2002cited by this paper
• Chronic hepatitis B.

  2002cited by this paper
• Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

  2002cited by this paper
• Safety of blood supply for infectious diseases in Latin American countries, 1994-1997.

  2001cited by this paper
• Hepatitis B Virus Infection in Children and Adolescents in a Hyperendemic Area: 15 Years after Mass Hepatitis B Vaccination

  2001cited by this paper
• Cross-Resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus

  2001cited by this paper
• Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B

  2001cited by this paper
• Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection

  2001cited by this paper
• Viral suppression and HBeAg-seroconversion following long-term adefovir dipivoxil therapy in chronic hepatitis B infection.

  2001cited by this paper
• Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States.

  2001cited by this paper
• A randomized, double‐blind trial comparing pegylated interferon alfa‐2b to interferon alfa‐2b as initial treatment for chronic hepatitis C

  2001cited by this paper
• Economic analysis of a child vaccination project among Asian Americans in Philadelphia, Pa.

  2001cited by this paper
• Hepatitis B Virus Infection in Native versus Immigrant or Adopted Children in Italy Following the Compulsory Vaccination

  2001cited by this paper
• Efficacy and safety of pegylated (40‐kd) interferon α‐2a compared with interferon α‐2a in noncirrhotic patients with chronic hepatitis C

  2001cited by this paper
• Serologic and Clinical Outcomes of 1536 Alaska Natives Chronically Infected with Hepatitis B Virus

  2001cited by this paper
• The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B

  2001cited by this paper
• [Chronic hepatitis B].

  2001cited by this paper
• Economic evaluation of the societal costs of hepatitis B in South Korea

  2001cited by this paper
• Liver cancer.

  2001cited by this paper
• Risk Factors for Hepatocellular Carcinoma in Turkey

  2001cited by this paper
• Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

  2001cited by this paper
• International trends and patterns of primary liver cancer

  2001cited by this paper
• Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.

  2001cited by this paper
• Estimating the world cancer burden: Globocan 2000

  2001cited by this paper
• Long-term morbidity and mortality in Chinese insurance applicants infected with the hepatitis B virus.

  2001cited by this paper
• Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000).

  2001cited by this paper
• The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B.

  2001cited by this paper
• Management of hepatitis B: 2000--summary of a workshop.

  2001cited by this paper
• Epidemiology of hepatocellular carcinoma.

  2000cited by this paper
• Evolution of hepatitis B virus polymerase gene mutations in hepatitis B e Antigen–negative patients receiving lamivudine therapy

  2000cited by this paper
• Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial

  2000cited by this paper
• Pegylated interferon‐α2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data

  2000cited by this paper
• Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea

  2000cited by this paper
• PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS PEGINTERFERON ALFA-2a IN PATIENTS WITH CHRONIC HEPATITIS C AND CIRRHOSIS

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis.

  2000cited by this paper
• Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine.

  2000cited by this paper
• Hepatitis B and C viruses in the etiology of hepatocellular carcinoma; a study in Greece using third-generation assays

  2000cited by this paper
• Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium

  2000cited by this paper
• Peginterferon alfa-2a in patients with chronic hepatitis C.

  2000cited by this paper
• The impact of the hepatitis B mass immunisation campaign on the incidence and risk factors of acute hepatitis B in Italy.

  2000cited by this paper
• Epidemiology of hepatitis B virus infection in the Asia–Pacific region

  2000cited by this paper
• Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B

  2000cited by this paper
• Famciclovir treatment of anti-HBE+ chronic hepatitis B: Results of a randomized, placebo-controlled study

  2000cited by this paper
• Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  2000cited by this paper
• The 20th United States–Japan joint hepatitis panel meeting

  2000cited by this paper
• Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants

  2000cited by this paper
• Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group.

  2000cited by this paper
• Rising Incidence of Hepatocellular Carcinoma in the United States

  1999cited by this paper
• Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy

  1999cited by this paper
• A placebo‐controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection

  1999cited by this paper
• Retreatment of chronic hepatitis B e antigen–positive patients with recombinant interferon alfa‐2a

  1999cited by this paper
• Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates.

  1999cited by this paper
• Lamivudine as initial treatment for chronic hepatitis B in the United States.

  1999cited by this paper
• Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors.

  1999cited by this paper
• Unsafe injections in the developing world and transmission of bloodborne pathogens: a review.

  1999cited by this paper
• Health care costs associated with chronic hepatitis B.

  1999cited by this paper
• Update on Diagnosis, Management, and Prevention of Hepatitis B Virus Infection

  1999cited by this paper
• Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Lamivudine Precore Mutant Study Group.

  1999cited by this paper
• Long term response to therapy of chronic anti-HBe–positive Hepatitis B is poor independent of type and schedule of interferon

  1999cited by this paper
• Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

  1999cited by this paper
• Immunization programme against hepatitis B virus infection in Italy: cost-effectiveness.

  1999cited by this paper
• Long-term follow-up of a randomized trial of interferon therapy for chronic hepatitis B in a predominantly homosexual male population.

  1999cited by this paper
• Rising incidence of hepatocellular carcinoma in the United States.

  1999cited by this paper
• Clinical Pharmacokinetics of Lamivudine

  1999cited by this paper
• Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea.

  1998cited by this paper
• Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action.

  1998cited by this paper
• Unsafe injections.

  1998cited by this paper
• Characteristics of hepatocellular carcinoma in Italy.

  1998cited by this paper
• Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus

  1998cited by this paper
• A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  1998cited by this paper
• The epidemiology, treatment patterns and resource utilization of hepatitis B patients in a Large Insured New England population*

  1998cited by this paper
• Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group.

  1997cited by this paper
• Hepatitis B virus infection.

  1997cited by this paper
• The 18th United States‐Japan Joint Hepatitis Panel Meeting

  1997cited by this paper
• A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum

  1997cited by this paper
• Long‐term outcome of hepatitis B e antigen–positive patients with compensated cirrhosis treated with interferon alfa

  1997cited by this paper
• Seroepidemiology of hepatitis B virus infection in children: Ten years of mass vaccination in Taiwan.

  1996cited by this paper
• Epidemiology of hepatitis B infection in the Western Pacific and South East Asia.

  1996cited by this paper
• Epidemiology of hepatocellular carcinoma.

  1995cited by this paper
• Cost-effectiveness of Interferon-2b Treatment for Hepatitis B e Antigen-Positive Chronic Hepatitis B

  1995cited by this paper
• Comparative study of three doses of interferon‐α2a in chronic active hepatitis B

  1994cited by this paper
• Comparative study of three doses of interferon-alpha 2a in chronic active hepatitis B. The International Hepatitis Trial Group.

  1994cited by this paper
• The cost effectiveness of alpha interferon in the treatment of chronic active hepatitis C

  1994cited by this paper
• Age at first establishment of chronic hepatitis B virus infection and hepatocellular carcinoma risk. A birth order study.

  1992cited by this paper
• Long-term remission of chronic hepatitis B after alpha-interferon therapy.

  1991cited by this paper
• A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group.

  1990cited by this paper
• Development of recommendations for control of hepatitis B virus infections: the role of cost analysis.

  1990cited by this paper
• A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

  1990cited by this paper
• Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen‐carrier mothers

  1989cited by this paper
• Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection.

  1989cited by this paper
• A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers.

  1987cited by this paper
• Two distinct types of hepatitis in experimental hepatitis B virus infection.

  1980cited by this paper
• Letter: Ondine's curse.

  1976cited by this paper

• Evaluating the Immunological Impact of Hepatitis B Vaccination in Patients with Inflammatory Bowel Disease

  2026cites this paper
• Feasibility and Challenges in Implementing Mother-To-Child Transmission (PMTCT) of Hepatitis B Infection in Resource-Limited Settings in Malaysia.

  2026cites this paper
• Causal association between blood immune cells and chronic hepatitis B: Univariable and multivariable Mendelian randomization

  2026cites this paper
• PEG chain length modulates hepatic targeting of GalNAc liposomes via ligand exposure and optimal glycocluster conformation

  2026cites this paper
• Impact of TNF-α (− 308G>A and − 857 C>T) promoter variants on susceptibility to chronic hepatitis B virus infection in a cohort of Mauritanian patients: pilot study

  2026cites this paper
• Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses

  2025cites this paper
• Matrigel and collagen I impact hepatocellular carcinoma cell behavior: a confluency-dependent study

  2025cites this paper
• Results in chronic hepatitis B patients using tenofovir and entecavir for at least 10 years; HBV clearance rare, disease outcomes good: An observational cohort study

  2025cites this paper
• UBE2O, a host ubiquitin-conjugating enzyme, is a key regulator of hepatitis B virus maturation and egress

  2025cites this paper
• Evaluation of the Potency of Repurposed Antiretrovirals in HBV Therapy: A Narrative Investigation of the Traditional Medicine Alternatives

  2025cites this paper
• The Multifaceted Antimicrobial Profile of Piperine in Infectious Disease Management: Current Perspectives and Potential

  2025cites this paper
• Predictive factors and clinical outcomes in decompensated non-cirrhotic chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate.

  2025cites this paper
• Modeling the impact of double dose vaccination and vertical transmission on hepatitis B with saturated incidence and optimal control

  2025cites this paper
• The role of spontaneous clearance on fractional analysis of HBV

  2025cites this paper
• Viral hepatitis B co-infection among people living with HIV: a National cross-sectional survey in Togo in 2023

  2025cites this paper
• Hepatitis B Virus Seroprevalence in Ayacucho, Peru: A Comprehensive Review Across the Pre-Vaccination and Post-Vaccination Periods

  2025cites this paper
• Seroprevalence and associated factors of Hepatitis B virus among diabetic adult patients attending at Haramaya General Hospital, Eastern Ethiopia

  2025cites this paper
• Knowledge, Attitude, and Practice of the Medical Students of the University of Medical Sciences and Technology Towards Hepatitis B Virus Infection

  2025cites this paper
• Causal relationship between chronic hepatitis B infection and gastric ulcer: A Mendelian randomization study

  2025cites this paper
• Potential for Core Fucose-Targeted Therapy Against HBV Infection of Human Normal Hepatocytes

  2025cites this paper
• Efficacy of intradermal plus intramuscular Recombinant hepatitis B vaccination in vaccine nonresponders.

  2025cites this paper
• Tenofovir alafenamide for prevention of HBV reactivation in HBsAg-negative, anti–HBc-positive patients undergoing rituximab-based chemotherapy: A multicenter randomized controlled trial

  2025cites this paper
• Evaluation of platelet parameters in HBsAg positive somalian patients.

  2025cites this paper
• Unveiling the Silent Crisis Amidst Tackling Hepatitis B in African Prisons ‐ A Public Health Emergency

  2025cites this paper
• Burden of psychological symptoms and disorders among individuals with hepatitis B: a systematic review, meta-analysis and meta-regression

  2025cites this paper
• Monitoring of hepatitis B infection in the elderly population of eastern Iran

  2025cites this paper
• Geographic disparities in hepatitis B vaccine coverage across Africa: Implications for targeted interventions and 2030 goals.

  2025cites this paper
• AND Logic Gate-Based Dual-Specificity DNA Circuit for Isothermal HBV rcDNA Detection

  2025cites this paper
• Progress in American Scholars’ Research on the High Prevalence of Hepatitis B among Asian Americans Since the End of the 20th Century

  2025cites this paper
• Synergistic impact of high body-mass index on HBV/HCV-related liver cancer burden globally: Analysis and projections 1990-2050.

  2025cites this paper
• TCR-based cellular immunotherapy for hepatocellular carcinoma: advances, challenges, and prospects

  2025cites this paper
• HBV-induced N6 methyladenosine modification of PARP1 enhanced AFB1-related DNA damage and synergistically contribute to HCC.

  2025cites this paper
• A research protocol for a prospective, multicenter, cohort study on interferon therapy for chronic hepatitis B combined with metabolism-associated fatty liver disease to achieve clinical cure

  2025cites this paper
• Seroprevalence and Risk Factors of Hepatitis B Virus Among Newly Diagnosed Cancer Patients in Khartoum State: Implications for Chemotherapy Management and Screening Protocols

  2025cites this paper
• HBV MUTATION AND DYNAMICS IN SUB-SAHARAN AFRICA: MODELING, ANALYSES, AND SIMULATION

  2025cites this paper
• Viral oncogenesis in cancer: from mechanisms to therapeutics

  2025cites this paper
• Harnessing polydiacetylene (PDA): A review of structural mechanics and infectious disease detection

  2025cites this paper
• The Use of Artificial Intelligence in Data Analysis with Error Recognitions in Liver Transplantation in HIV-AIDS Patients Using Modified ABC Fractional Order Operators

  2024cites this paper
• Agent based modelling of blood borne viruses: a scoping review

  2024cites this paper
• II. Diagnosis and treatment of chronic hepatitis virus infection

  2024cites this paper
• Sero-prevalence and risk factors for maternal and umbilical cord hepatitis B surface antigenaemia at delivery in a South-West Nigerian State

  2024cites this paper
• Novel mechanistic insights - A brand new Era for anti-HBV drugs.

  2024cites this paper
• Hepatitis and Hepatitis B Virus Reactivation in Everolimus-Treated Solid Tumor Patients: A Focus on HBV-Endemic Areas

  2024cites this paper
• Vaccination contre l’hépatite B

  2024cites this paper
• Characteristics and antiviral treatment eligibility of patients diagnosed with hepatitis B at a teaching hospital in Ghana: Implications for prevention and management

  2024cites this paper
• Sex-specific associations of Notch signaling with chronic HBV infection: a study from Taiwan Biobank

  2024cites this paper
• Performance of noninvasive fibrosis indices in chronic hepatitis B during pretreatment and post-treatment periods.

  2024cites this paper
• Hepatitis B Surface Antigen Isoforms: Their Clinical Implications, Utilisation in Diagnosis, Prevention and New Antiviral Strategies

  2024cites this paper
• Insights Into Hepatitis B Awareness and Vaccination Trends Among Healthcare Providers: A Comprehensive Study

  2024cites this paper
• Reactivation of Hepatitis B Virus among Malignancy Patients Undergoing Chemotherapy: A Prospective Cohort Study

  2024cites this paper
• Bibliometric analysis of entecavir for the treatment of cirrhosis in hepatitis B.

  2024cites this paper
• Antiviral Effect of Ferula Plants and their Potential for Treatment of COVID-19: A Comprehensive Review.

  2024cites this paper
• Comparison of Hepatitis B Surface Antibody Levels After Vaccination With Combined One Dose of Hexavalent Vaccine and Two Doses of Pentavalent Vaccine Versus Three Doses of Pentavalent Vaccine

  2024cites this paper
• Seroprevalence of Hepatitis B Virus Infection and Associated Factors among Cancer Patients at Hawassa University Comprehensive Specialized Hospital, Ethiopia.

  2024cites this paper
• The Prevalence of Hepatitis B Virus among Full-Term Mothers and their Infants at El-Obeid Teaching Hospital, Sudan

  2024cites this paper
• Schists of Nuwiba area, southeast Sinai, Egypt: Field, Petrographic, Geochemical and Radiometric Aspects

  2024cites this paper
• Monitoring of hepatitis B infection in the elderly population of eastern Iran

  2024cites this paper
• Seropositivity and coinfection of hepatitis B and hepatitis C viruses in Central India: A hospital-based study

  2024cites this paper
• “Putting the power back into community”: A mixed methods evaluation of a chronic hepatitis B training course for the Aboriginal health workforce of Australia’s Northern Territory

  2024cites this paper
• Does Alexithymia Predict the Psychiatric Comorbidity Among Healthy Carriers of Hepatitis B?

  2024cites this paper
• Anti-HBsAg IgY polyclonal antibodies potential as capture antibody for HBsAg Detection Kit development

  2024cites this paper
• Protektem pikinini blong yu trial: protocol for a single arm field trial to assess the effectiveness of treating-all pregnant women with hepatitis B infection with tenofovir prophylaxis to prevent mother-to-child transmission in Vanuatu, 2024–2025

  2024cites this paper
• Maternal infection with hepatitis B virus before pregnancy and risk of congenital malformations in offspring: a record-linkage study of a large national sample from China

  2024cites this paper
• Practices for preventing Hepatitis B infection among health science students in Ethiopia: Systematic review and meta-analysis

  2024cites this paper
• Dynamics of HBV infection model with DNA-containing capsids, logistic hepatocyte growth and adaptive immune response

  2024cites this paper
• Modeling and analysis of the fractional-order epidemic model to investigate mutual influence in HIV/HCV co-infection

  2024cites this paper
• Exploring the evolutionary mechanism of hepatitis B and gastric cancer based on Mendelian randomization combined with bioinformatics analysis

  2024cites this paper
• Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future

  2024cites this paper
• Epidemiology and Management of Infections in Liver Transplant Recipients

  2024cites this paper
• Hepatocyte Intrinsic Innate Antiviral Immunity against Hepatitis Delta Virus Infection: The Voices of Bona Fide Human Hepatocytes

  2024cites this paper
• Determinants of mother-to-child transmission of hepatitis B virus among pregnant women in southwestern Nigeria

  2024cites this paper
• Preparation and Evaluation of Primary Reagents for the Radioimmunoassay of Hepatitis B Surface Antigen (HBsAg) for its Diagnosis in Human Sera

  2024cites this paper
• The literature discusses oral manifestations caused by sexually transmitted viruses: a narrative review.

  2024cites this paper
• Seroepidemiology of hepatitis B virus (HBV) and relationship to serum transaminase levels in Indian population

  2024cites this paper
• Article Review: The Hepatic Physiology and Pathophysiology of Different Types of Hepatitis

  2024cites this paper
• Modeling different infectious phases of hepatitis B with generalized saturated incidence: An analysis and control.

  2024cites this paper
• Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy – A systematic review and meta‐analysis

  2024cites this paper
• Viral Hepatitis B and C: Epidemiological, Clinical and Paraclinical Aspects in the Internal Medicine Department of KARA University Hospital in Togo

  2024cites this paper
• Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation

  2024cites this paper
• Hepatitis B virus as a risk factor for hepatocellular carcinoma: There is still much work to do

  2024cites this paper
• Hepatitis B clinical care provision in pregnancy: A whole‐of‐population linkage study in Victoria, Australia

  2024cites this paper
• A systematic review reveals that African children of 15–17 years demonstrate low hepatitis B vaccine seroprotection rates

  2023cites this paper
• Prevalence of Viral Hepatitis B among Women of Childbearing Age in the Kara Region of Togo in 2022

  2023cites this paper
• Changes and gaps of global and regional disease burden of hepatitis B infection in children younger than 5 years old between 2015 and 2019: A real‐world data review

  2023cites this paper
• Hepatitis Flares or Hepatic Decompensation after Discontinuation of Tenofovir Disoproxil Fumarate and Entecavir in Non-Cirrhotic Hepatitis B e Antigen-Negative Patients

  2023cites this paper
• Expert System for Medical Predictions of Hepatitis B

  2023cites this paper
• Impact of nucleos(t)ide analogues on the risk of hepatocellular carcinoma in chronic hepatitis B patients: A time-dependent Cox regression analysis.

  2023cites this paper
• In vitro evaluation of tropolone absorption, metabolism, and clearance.

  2023cites this paper
• A Resilience Approach for Diagnosing and Predicting HBV-Related Diseases based on Blood Tests

  2023cites this paper
• Antimicrobial Properties of Capsaicin: Available Data and Future Research Perspectives

  2023cites this paper
• The effect of hepatitis B virus on the risk of pregnancy outcomes: a systematic review and meta-analysis of cohort studies

  2023cites this paper
• Systemic lupus erythematosus is associated with lower risk of hepatitis B virus infection: A multivariable Mendelian randomization study in East Asian population

  2023cites this paper
• Hepatitis B Virus in Cirrhosis and Primary Livers Cancers

  2023cites this paper
• A Fractional dynamics model of hepatitis B disease spread under influence of campaign and treatment

  2023cites this paper
• Rapid and sensitive LAMP/CRISPR-powered diagnostics to detect different hepatitis C virus genotypes using an ITO-based EG-FET biosensing platform

  2023cites this paper
• Conocimientos y actitudes sobre hepatitis B en internos de medicina humana de las universidades acreditadas en la región Lambayeque, Perú, 2020

  2023cites this paper
• Difference of gut microbiota between patients with negative and positive HBeAg in chronic hepatitis B and the effect of tenofovir alafenamide on intestinal flora

  2023cites this paper
• Application of a Caprylate/Chromatography Purification Process for Production of a Hepatitis B Immune Globulin from Pooled Human Plasma

  2023cites this paper
• Vaccination Campaign against Hepatitis B Virus in Italy: A History of Successful Achievements

  2023influential citation
• Five Decades of HBV Infection in Italy: A Continuous Challenge

  2023cites this paper